Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

In addition to Dupixent as “the foundation and the cornerstone” in type 2 inflammatory diseases, CEO Paul Hudson noted Sanofi currently has 10 molecules in development in the area, including ...

If approved, Dupixent would gain access to an addressable market of at least 75,000 patients. This indication could generate $1.4 billion in annual revenue for Sanofi and Regeneron to split. The ...

Dupixent ® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis Only biologic approved in the European Union for patients aged 12 and above with ...

Sanofi previously forecast Dupixent would generate up to 13 billion euros ($14.2 billion) in sales in its best year as it seeks to widen its use across several inflammatory conditions, but it has ...

Dupixent is Sanofi’s top-selling product. Across all of its approved indications, the drug accounted for more than €10.7 billion (about $11.6 billion) in global revenue last year, ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...